Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex Dose-Finding Study for Reversal of Neuromuscular Blockade
NCT03519854Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2002
- Primary completion
- Jun 2003
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
A Phase 2 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co.. Started Dec 2002; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03519854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519854.